Apply generative models to pharmaceutical research and drug discovery.
Insilico Medicine Funding History
Insilico Medicine uses generative AI for drug discovery. Its work spans target identification, molecule design and preclinical and clinical development.
Company Overview
Insilico Medicine
Founded 2014 · Hong Kong
Official WebsiteInsilico Medicine Funding Timeline
Series E
US$110 million
Insilico raised the round as it developed its AI drug discovery platform and advanced its pipeline of drug candidates.
Led by Value Partners Group.
Source · prnewswire.com ↗Series D
US$60 million
Insilico said the funds would expand its drug pipeline and help establish a laboratory that combined AI with robotics.
Source · prnewswire.com ↗Series C
US$255 million
Insilico said it would use the proceeds to move therapeutic programs into human trials and start additional drug discovery projects.
Led by Warburg Pincus.
Source · prnewswire.com ↗
Insilico Medicine Founding Team
Alex Zhavoronkov founded Insilico Medicine to apply AI to questions in aging and drug discovery. His early work at the company used biological data to study disease mechanisms and identify potential drug targets.
Insilico Medicine Products
Insilico Medicine Company Development
Connecting Molecule Design to the Laboratory
Insilico joined its computational drug discovery work to an internal pipeline and announced plans for a robotics laboratory in 2022. The lab plans added an experimental step to a process that starts with identifying targets and designing molecules.
Insilico Medicine Competitive Landscape
Generating Molecules and Profiling Biology
Insilico’s Pharma.AI spans target identification and molecule design. Insitro emphasizes large-scale measurements of human biology that can teach models which targets are relevant to disease. Both bring computation into drug discovery, with different starting points for the experimental work.
